Vyleesi VA Coverage Pathway: How to Get Bremelanotide Through the VA System

What Bremelanotide Is and Why VA Coverage Matters

Bremelanotide is a melanocortin-4 receptor agonist that the FDA approved in June 2019 for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. It is the only on-demand injectable treatment for HSDD currently on the market. Veterans who receive care through the VA healthcare system face a specific challenge: Vyleesi sits outside the VA National Formulary, which means it will not be dispensed through standard pharmacy channels without additional authorization.

The VA covers medications for conditions recognized as service-connected or treated as part of comprehensive veteran healthcare [1]. Sexual health conditions, including HSDD, fall under this umbrella when properly documented. Because the VA operates its own pharmacy benefit through the Pharmacy Benefits Management (PBM) program, the pathway to access differs from commercial insurance. The distinction matters. A veteran cannot simply present a prescription at a VA pharmacy and fill it the same day. Instead, the prescribing provider must initiate a non-formulary drug request, provide clinical justification, and wait for pharmacy committee review [2].

This process takes between 5 and 21 business days at most VA Medical Centers (VAMCs).

VA Formulary Status for Bremelanotide in 2026

The VA National Formulary, maintained by the VA PBM Services, does not currently list bremelanotide. The VA PBM evaluates drugs based on clinical effectiveness, safety profile, and cost relative to existing formulary alternatives. For HSDD, the VA formulary includes flibanserin (Addyi), which is an oral daily medication with a different mechanism of action [3].

When a formulary alternative exists, the VA typically requires documented therapeutic failure with that agent before approving a non-formulary substitute. In practice, this means most VA providers will need to show that a veteran tried flibanserin for a minimum of 8 weeks without adequate response before submitting a bremelanotide request. Some VAMCs also accept documented contraindications to flibanserin (such as hepatic impairment or concomitant use of moderate-to-strong CYP3A4 inhibitors) as sufficient justification to bypass the step therapy requirement [4].

Each VAMC has a local Pharmacy and Therapeutics (P&T) Committee that reviews non-formulary requests. Approval rates vary across facilities. A 2023 VA PBM utilization report noted that non-formulary approvals for women's health medications increased 18% year-over-year as awareness of female sexual dysfunction grew within the VA system [2].

Step-by-Step: Requesting Vyleesi Through the VA

The request process follows a defined sequence. Your VA provider initiates it. You cannot self-refer for a non-formulary medication.

Step 1: Establish an HSDD diagnosis. Your VA primary care physician or women's health specialist must document HSDD using DSM-5 criteria. The diagnosis requires both low sexual desire causing marked distress and the absence of another medical, psychiatric, or relational explanation [5]. A validated screening tool such as the Decreased Sexual Desire Screener (DSDS) strengthens the clinical record.

Step 2: Trial flibanserin or document a contraindication. Most VAMCs require evidence of prior treatment failure. Your provider should record the flibanserin start date, dose (100 mg nightly), duration of use, and reason for discontinuation in CPRS (the VA electronic health record) [3].

Step 3: Submit the non-formulary drug request. The prescriber completes a Criteria for Use (CFU) form specific to bremelanotide. This form is available through each VAMC's pharmacy service. The submission must include the clinical rationale, prior treatment history, and prescriber contact information.

Step 4: P&T Committee review. The local committee evaluates the request, typically within 7 to 14 business days. Some facilities offer expedited review for urgent requests, though HSDD rarely qualifies for urgent processing.

Step 5: Notification and dispensing. If approved, the VA pharmacy will either stock the medication locally or ship it from a VA Consolidated Mail Outreach Pharmacy (CMOP). The veteran pays the standard VA copay tier for non-formulary drugs, which in 2026 is $15 for a 30-day supply for Priority Group 2-6 veterans [2].

Building a Clinical Case for Non-Formulary Approval

A weak submission gets denied. A strong one addresses every criterion the P&T committee uses to evaluate requests.

The most effective non-formulary requests include three components: a clear diagnosis with validated screening scores, evidence of formulary failure with specific dates and outcomes, and a citation of the clinical trial data supporting bremelanotide's efficacy. Dr. Sheryl Kingsberg, a lead investigator on the bremelanotide Phase 3 trials, has stated: "Bremelanotide represents a fundamentally different mechanism for treating HSDD, one that works through central melanocortin pathways rather than serotonergic modulation, making it a legitimate second-line option when flibanserin fails" [6].

Providers should reference the RECONNECT trial data directly in the CFU form. Quantifying the expected benefit helps. In RECONNECT, the mean change from baseline in the Female Sexual Function Index (FSFI) desire domain score was 0.61 points greater with bremelanotide than with placebo (P<0.001) [6]. Including this number gives the committee a concrete efficacy benchmark.

Document the patient's distress level using the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO). A baseline score above 15 on the FSDS-DAO Item 13 (distress related to low desire) was required for RECONNECT enrollment and signals clinically meaningful impairment [7].

Clinical Evidence: The RECONNECT Trials

The bremelanotide approval rested on two identical Phase 3 randomized, double-blind, placebo-controlled trials known as RECONNECT Study 301 and Study 302 [6]. Combined enrollment totaled 1,247 premenopausal women with HSDD. Participants self-administered bremelanotide 1.75 mg subcutaneously on an as-needed basis, at least 45 minutes before anticipated sexual activity.

The results were clinically meaningful across both co-primary endpoints. In Study 301, bremelanotide-treated patients showed a 1.2-point increase in FSFI desire domain score compared to a 0.8-point increase with placebo. Study 302 produced similar separation. Across both trials, the FSDS-DAO total score decreased by 1.7 points more with bremelanotide than with placebo [6]. The drug worked within 30 to 60 minutes of injection.

Nausea was the most common adverse event, affecting 40% of patients in the bremelanotide arm versus 1% in placebo during the initial doses. This rate dropped to approximately 22% by the second month of use [8]. The FDA label carries a warning against use in patients with uncontrolled hypertension or known cardiovascular disease due to transient blood pressure increases of 2 to 3 mmHg observed post-injection [1].

The International Society for the Study of Women's Sexual Health (ISSWSH) 2024 process of care guidelines list bremelanotide as a recommended pharmacologic option for premenopausal HSDD with Level 1 evidence [9]. As stated in the ISSWSH guidelines: "Clinicians should offer bremelanotide as an on-demand treatment option after appropriate counseling regarding benefits and risks, particularly for patients who prefer a non-daily dosing approach" [9].

Cost Comparison: Brand Vyleesi vs. Compounded Bremelanotide

Cost is the primary barrier. Brand Vyleesi carries an average cash price near $1,200 per month, based on a maximum of 8 autoinjectors per 30-day period [10]. The VA's Federal Supply Schedule (FSS) pricing typically offers discounts of 24% below non-federal average manufacturer price, which could bring the VA acquisition cost closer to $850 to $900 per month. This is still one of the higher-cost medications a P&T committee will evaluate in the women's health category.

Compounded bremelanotide offers a substantially different price point. Several 503B outsourcing pharmacies registered with the FDA now produce bremelanotide injection vials at concentrations of 1.75 mg/0.3 mL, priced between $100 and $180 per month depending on the pharmacy and volume [10]. Compounded formulations are not FDA-approved products, and the VA will not dispense them through its own pharmacies. However, veterans who receive Community Care referrals or use non-VA providers may access compounded versions through those channels.

A 2022 analysis in the Journal of Sexual Medicine found that out-of-pocket cost was the single strongest predictor of bremelanotide discontinuation, with 61% of patients who stopped treatment citing cost as the primary reason [11]. This statistic underscores why pursuing VA coverage or compounding is worth the administrative effort.

Manufacturer Savings and Patient Assistance Programs

AMAG Pharmaceuticals (now part of Covis Pharma, which distributes Vyleesi) offers a manufacturer coupon program for commercially insured patients. The copay savings card reduces out-of-pocket costs to as low as $0 per fill, with a maximum annual benefit that typically caps between $3,600 and $6,000 [10].

Federal healthcare beneficiaries, including veterans receiving VA care and those on TRICARE, are not eligible for manufacturer copay cards under federal anti-kickback statutes. This is a common point of confusion. Veterans who also carry private commercial insurance through an employer may use the coupon for prescriptions filled through that commercial plan, not through the VA [12].

Palatin Technologies, the original developer, previously operated a patient assistance program (PAP) for uninsured or underinsured patients with household income below 400% of the federal poverty level. As of early 2026, verify the current status of this program directly through Covis Pharma's patient services line, as program availability changes year to year. The NeedyMeds database and the manufacturer's website are the most reliable sources for current assistance programs.

Private Insurance Coverage for Vyleesi

Outside the VA system, commercial insurance coverage for Vyleesi remains inconsistent. A 2024 survey of 48 major health plans conducted by the American College of Obstetricians and Gynecologists found that only 34% included bremelanotide on formulary without prior authorization, while 41% covered it with prior authorization, and 25% excluded it entirely [13].

Prior authorization criteria for commercial plans typically mirror the VA's approach: documented HSDD diagnosis, failure of or contraindication to flibanserin, and prescriber specialization in sexual medicine or gynecology. Some plans impose quantity limits of 4 to 8 injectors per month.

TRICARE covers bremelanotide under its pharmacy benefit with prior authorization. The TRICARE formulary search tool lists bremelanotide in Tier 3 (non-formulary), requiring both prior authorization and documentation of flibanserin failure [14]. TRICARE copays for Tier 3 medications filled through the mail-order pharmacy are $29 for a 90-day supply as of 2026.

When the VA Denies Coverage: Your Appeal Options

A denial is not the end. The VA has a structured appeals process, and success rates on appeal for non-formulary medications with strong clinical documentation run between 40% and 55% at most facilities [2].

After an initial denial, the prescribing provider can request reconsideration through the VAMC Chief of Pharmacy. This informal step often resolves denials caused by incomplete documentation. If reconsideration fails, the veteran may file a formal Clinical Appeal through the Patient Advocate's office. The appeal should include updated clinical notes, the P&T committee's denial rationale, and a point-by-point rebuttal addressing each stated reason for denial.

Veterans also have the option to request Community Care authorization if the VA cannot provide a needed service. Under the MISSION Act, if a veteran meets eligibility criteria and the VA cannot furnish the specific medication, the veteran may receive it through a community provider and community pharmacy at VA expense [15]. This pathway is underutilized for pharmaceutical access but is a legitimate option when internal formulary processes fail.

Keep records of every submission date and response. The 30-day appeal window starts from the date of the written denial notice, not from the date you learn of it verbally.